Related Experiment Video
Updated: May 16, 2025
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
Published on: April 26, 2016
Formulation optimization and characterization of Central composite design optimized LAP-loaded calcium pectinate
Abhishek Chauhan1, Abhishek Verma2, Raj Kamal3
1Chitkara College of Pharmacy, Chitkara University, Punjab, India.
Objective:
The study aimed to formulate and optimize Lapatinib-loaded calcium pectinate nanoparticles (LAP-PEC-NPs) using central composite design (CCD), evaluate their physicochemical properties, and compare their anticancer efficacy with raw LAP on MCF7 breast cancer cell lines.
Significance Of Review:
The study is significant as it successfully developed LAP-PEC-NPs through systematic optimization. These nanoparticles exhibited favorable physicochemical properties, high drug entrapment, and sustained release. The effective inhibition of MCF7 breast cancer cell growth by LAP-PEC-NPs underscores their potential as a promising cancer treatment strategy, enhancing LAP's therapeutic efficacy and bioavailability.
Key Findings:
LAP-PEC-NPs were successfully developed using an ionic gelation process. The optimization resulted in an ideal formulation with a polydispersity index (PDI) of 0.289, a droplet size of 93.65 nm, and a zeta potential of -17.32 mV. LAP's amorphous nature within the nanoparticles' porous matrix was confirmed through characterization techniques. Dissolution studies showed sustained drug release, with LAP-PEC-NPs releasing approximately 75% of LAP over 72 h, significantly higher than raw LAP. Evaluation of MCF7 breast cancer cell lines revealed that LAP-PEC-NPs effectively inhibited cell growth.
Conclusions:
The study successfully developed and optimized LAP-PEC-NPs, yielding nanoparticles with desirable characteristics. The sustained drug release kinetics and promising anticancer efficacy of LAP-PEC-NPs suggest their potential as a therapeutic strategy for breast cancer treatment. These findings pave the way for further preclinical and clinical studies to validate the efficacy and safety of LAP-PEC-NPs for clinical translation.
